<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885079</url>
  </required_header>
  <id_info>
    <org_study_id>037E-08-001</org_study_id>
    <nct_id>NCT00885079</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of OPC-12759 Ophthalmic Suspension</brief_title>
  <official_title>Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify whether OPC-12759 ophthalmic suspension is effective
      compared with active control in dry eye patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fluorescein Corneal Staining (FCS) Score From Baseline</measure>
    <time_frame>Baseline, Weeks4</time_frame>
    <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. Noninferiority for change from baseline in the FCS score (LOCF) was determined by comparing the noninferiority margin (0.4) with the upper limit of the 95% confidence interval (CI) of the difference between the 2 treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline</measure>
    <time_frame>Baseline, Weeks4</time_frame>
    <description>LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining sdore from 0 to 3, and the total score was calculated (0-18). 0 is better. Superiority was verified by comparing t-test results for change from baseline in the LGCS score (LOCF) between 2 treatment groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Rebamipide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instillation,4 times/day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Instillation,6 times/day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-12759 Ophthalmic suspension</intervention_name>
    <description>OPC-12759 Ophthalmic suspension 2%</description>
    <arm_group_label>Rebamipide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyalein Mini Ophthalmic solution</intervention_name>
    <description>Hyalein Mini Ophthalmic solution 0.1%</description>
    <arm_group_label>Hyaluronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Out patient

          2. Subjective complaint of dry eye that has been present for minimum 20 months

          3. Ocular discomfort severity is moderate to severe

          4. Corneal - conjunctival damage is moderate to severe

          5. Unanesthetized Schirmer's test score of 5mm/5minutes or less

          6. Best corrected visual acuity of 0.2 or better in both eyes

        Exclusion Criteria:

          1. Presence of anterior segment disease or disorder other than that associated with
             keratoconjunctivitis sicca

          2. Ocular hypertension patient or glaucoma patient with ophthalmic solution

          3. Anticipated use of any topically-instilled ocular medications or patients who cannot
             discontinue the use during the study

          4. Anticipated use of contact lens during the study

          5. Patient with punctal plug

          6. Any history of ocular surgery within 12 months

          7. Female patients who are pregnant,possibly pregnant or breast feeding

          8. Known hypersensitivity to any component of the study drug or procedural medications

          9. Receipt of any investigational product within 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eiji Murakami</last_name>
    <role>Study Chair</role>
    <affiliation>OPCJ-DDO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyushu region</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chushikoku region</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai region</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai region</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto region</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2013</results_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rebamipide</title>
          <description>Instillation,4 times/day for 4 weeks
OPC-12759 Ophthalmic suspension : OPC-12759 Ophthalmic suspension 2%</description>
        </group>
        <group group_id="P2">
          <title>Hyaluronate</title>
          <description>Instillation,6 times/day for 4 weeks
Hyalein Mini Ophthalmic solution : Hyalein Mini Ophthalmic solution 0.1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rebamipide</title>
          <description>Instillation,4 times/day for 4 weeks
OPC-12759 Ophthalmic suspension : OPC-12759 Ophthalmic suspension 2%</description>
        </group>
        <group group_id="B2">
          <title>Hyaluronate</title>
          <description>Instillation,6 times/day for 4 weeks
Hyalein Mini Ophthalmic solution : Hyalein Mini Ophthalmic solution 0.1%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="17.7"/>
                    <measurement group_id="B2" value="55.2" spread="16.9"/>
                    <measurement group_id="B3" value="56.6" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline</title>
        <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. Noninferiority for change from baseline in the FCS score (LOCF) was determined by comparing the noninferiority margin (0.4) with the upper limit of the 95% confidence interval (CI) of the difference between the 2 treatment groups</description>
        <time_frame>Baseline, Weeks4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide</title>
            <description>Instillation,4 times/day for 4 weeks
OPC-12759 Ophthalmic suspension : OPC-12759 Ophthalmic suspension 2%</description>
          </group>
          <group group_id="O2">
            <title>Hyaluronate</title>
            <description>Instillation,6 times/day for 4 weeks
Hyalein Mini Ophthalmic solution : Hyalein Mini Ophthalmic solution 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline</title>
          <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. Noninferiority for change from baseline in the FCS score (LOCF) was determined by comparing the noninferiority margin (0.4) with the upper limit of the 95% confidence interval (CI) of the difference between the 2 treatment groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="0.3"/>
                    <measurement group_id="O2" value="-2.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for change from baseline in the FCS score was determined by comparing the non-inferiority margin (0.4) with the upper limit of the confidence interval of the difference between the 2 treatment groups.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>An analysis of change from baseline of FCS was performed using t-test. The level of singnificanse was 5 % (2-sided).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline</title>
        <description>LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining sdore from 0 to 3, and the total score was calculated (0-18). 0 is better. Superiority was verified by comparing t-test results for change from baseline in the LGCS score (LOCF) between 2 treatment groups.</description>
        <time_frame>Baseline, Weeks4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rebamipide</title>
            <description>Instillation,4 times/day for 4 weeks
OPC-12759 Ophthalmic suspension : OPC-12759 Ophthalmic suspension 2%</description>
          </group>
          <group group_id="O2">
            <title>Hyaluronate</title>
            <description>Instillation,6 times/day for 4 weeks
Hyalein Mini Ophthalmic solution : Hyalein Mini Ophthalmic solution 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline</title>
          <description>LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining sdore from 0 to 3, and the total score was calculated (0-18). 0 is better. Superiority was verified by comparing t-test results for change from baseline in the LGCS score (LOCF) between 2 treatment groups.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="3.2"/>
                    <measurement group_id="O2" value="-2.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.1</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rebamipide</title>
          <description>Instillation,4 times/day for 4 weeks
OPC-12759 Ophthalmic suspension : OPC-12759 Ophthalmic suspension 2%</description>
        </group>
        <group group_id="E2">
          <title>Hyaluronate</title>
          <description>Instillation,6 times/day for 4 weeks
Hyalein Mini Ophthalmic solution : Hyalein Mini Ophthalmic solution 0.1%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dysgeusia (bitter taste)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mr. Kyoji Imaoka</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>-81-6-6943-7722</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

